Page last updated: 2024-12-09

1-(4-methoxyphenyl)-3-(6-quinoxalinyl)thiourea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-(4-methoxyphenyl)-3-(6-quinoxalinyl)thiourea is a chemical compound with the molecular formula C17H14N4OS. It is a thiourea derivative, meaning it contains a thiourea functional group (NH2-CS-NH2).

The compound's structure includes a 4-methoxyphenyl ring and a 6-quinoxalinyl ring connected by the thiourea group. This specific arrangement of functional groups and aromatic rings contributes to its potential biological activity.

**Importance in Research:**

The specific importance of this compound for research depends on the context and application. However, thiourea derivatives are known to exhibit a wide range of biological activities, including:

* **Antimicrobial activity:** Thioureas are known to inhibit the growth of bacteria, fungi, and viruses. This compound might be investigated for its potential as an antimicrobial agent, particularly against specific pathogens.
* **Antioxidant activity:** Some thioureas have shown antioxidant properties, protecting cells from damage caused by free radicals. This could make 1-(4-methoxyphenyl)-3-(6-quinoxalinyl)thiourea relevant for research into oxidative stress and its role in various diseases.
* **Anticancer activity:** Thiourea derivatives have been studied for their anticancer potential, particularly against leukemia and solid tumors. This specific compound may be investigated for its ability to inhibit cancer cell growth and proliferation.
* **Enzyme inhibition:** Thioureas can act as inhibitors of certain enzymes, potentially impacting metabolic processes and disease development. This compound may be explored for its potential to modulate specific enzyme activities.

**Further Research:**

To determine the specific importance of 1-(4-methoxyphenyl)-3-(6-quinoxalinyl)thiourea, further research is required. This may involve:

* **Biological activity assays:** Testing the compound against various pathogens, cell lines, and enzymes to assess its potential efficacy.
* **Mechanism of action studies:** Investigating how the compound interacts with biological targets and exerts its effects.
* **Pharmacokinetic and toxicological studies:** Assessing the compound's absorption, distribution, metabolism, and excretion in the body, as well as its potential toxicity.

Overall, 1-(4-methoxyphenyl)-3-(6-quinoxalinyl)thiourea represents a promising candidate for research into various biological activities and its potential for therapeutic applications. However, further investigation is needed to fully understand its specific properties and its potential role in medicine or other fields.

Cross-References

ID SourceID
PubMed CID972779
CHEMBL ID1427219
CHEBI ID114745

Synonyms (16)

Synonym
n-(4-methoxyphenyl)-n'-6-quinoxalinylthiourea
smr000200258
MLS000581626 ,
zinc00613132 ,
CHEBI:114745
1-(4-methoxyphenyl)-3-quinoxalin-6-ylthiourea
HMS2551L10
1-(4-methoxyphenyl)-3-(6-quinoxalinyl)thiourea
bdbm34735
cid_972779
1-(4-methoxyphenyl)-3-quinoxalin-6-yl-thiourea
CHEMBL1427219
Q27196151
sr-01000280981
SR-01000280981-1
SDCCGSBI-0137243.P001
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinoxaline derivativeAny naphthyridine derivative that is a derivative of quinoxaline (1,4-naphthyridine).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (22)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency3.97160.140911.194039.8107AID2451
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency7.94330.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency39.81075.623417.292931.6228AID485281
LuciferasePhotinus pyralis (common eastern firefly)Potency26.85450.007215.758889.3584AID588342
thioredoxin reductaseRattus norvegicus (Norway rat)Potency15.84890.100020.879379.4328AID588453
phosphopantetheinyl transferaseBacillus subtilisPotency44.66840.141337.9142100.0000AID1490
ATAD5 protein, partialHomo sapiens (human)Potency14.58100.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency14.39790.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency12.58930.180013.557439.8107AID1460
thioredoxin glutathione reductaseSchistosoma mansoniPotency31.62280.100022.9075100.0000AID485364
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency25.11890.011212.4002100.0000AID1030
67.9K proteinVaccinia virusPotency31.62280.00018.4406100.0000AID720580
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency19.95260.035520.977089.1251AID504332
importin subunit beta-1 isoform 1Homo sapiens (human)Potency65.81145.804836.130665.1308AID540253; AID540263
snurportin-1Homo sapiens (human)Potency65.81145.804836.130665.1308AID540253; AID540263
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency11.22020.010323.856763.0957AID2662
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency75.68630.425612.059128.1838AID504891
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency31.62285.804816.996225.9290AID540253
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency26.65140.00798.23321,122.0200AID2546; AID2551
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
MPI proteinHomo sapiens (human)IC50 (µMol)50.00000.190013.825650.1000AID1220
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
signal transducer and activator of transcription 1-alpha/beta isoform alphaHomo sapiens (human)EC50 (µMol)13.32000.41801.36182.9980AID1397
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]